GW Pharma’s cannabis drug fails in cancer pain study, shares fall

By Ben Hirschler LONDON (Reuters) – An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday. GW, which is developing the drug Sativex for pain in collaboration with Japan’s Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo. …
Go to Source

AbbVie, Neurocrine drug successful in endometriosis trial

A sign sits in front of Shire's manufacturing facility in Lexington, Massachusetts(Reuters) – An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies. Neurocrine's stock soared 24 percent to $27.20 in premarket trading on Thursday, while AbbVie's shares were up 1.7 percent at $68.10. Endometriosis occurs when the lining of the uterus grows outside of the womb, leading to chronic pelvic pain. It is the leading cause of infertility. …

Go to Source

1 44 45 46 47 48 59